Sterling slumps on ‘no-deal Brexit’ worries; stocks dip
July 29, 2019
GM braces for attacks from Democrats in Detroit debates
July 29, 2019

Mylan deal puts future of its beleaguered EpiPen in spotlight

Mylan NV’s planned merger with Pfizer Inc’s off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Powered by WPeMatico